Chronix has first used the NGS technology for investigation into the use in breast cancer with very promising results. This is the background of our CNI-Evaluation test which has been developed into a sensitive and robust diagnostic assay since then.

Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010;8:335-42.